October 17, 2022

TTR Test Now Available In-House

Hereditary amyloidosis is a life-threatening disorder that can lead to peripheral neuropathy and heart failure. Early diagnosis and treatment of hereditary amyloidosis can provide a normal quality of life and lifespan for your patients. This new in-house test will be performed at our main laboratory for prompt results and is complementary to HNL Genomics Cardiology offerings.

The TTR test is a Sanger sequencing test that detects pathogenic variants in the TTR gene which cause hereditary transthyretin amyloidosis. These pathogenic variants change the structure of the TTR protein leading to the progressive buildup of amyloid protein in the body's organs, including the heart, kidneys, eyes, and gastrointestinal tract.


Use this test to pursue pharmacotherapies designed specifically for individuals with pathogenic TTR variants. Results provide valuable family medical history information that allow family members to pursue testing. If positive for a pathogenic variant, patients and family members may obtain an early diagnosis or be monitored for signs and symptoms before they occur.

Providers suspecting hereditary transthyretin amyloidosis can order this test easily in EPIC using code C7001. Our genetic testing experts are available to assist with any questions. Compared to three weeks with competitors, the turnaround time for our TTR test is just 7-14 days. Results are available in EPIC.

Test Summary

  • Transthyretin amyloidosis
  • Detects variants in TTR gene
  • EPIC Code C7001
  • Turnaround Time: 7-14 days

Time matters to your patients. HNL Lab Medicine delivers patient results quickly and conveniently. Take advantage of our newly available TTR test to provide superior patient care. For inquiry or assistance, please contact customer care at 877-402-4221. For clinical information or to discuss a patient, providers may also contact HNL Genomics at 484-244-2900.